196 related articles for article (PubMed ID: 30334063)
1. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression].
Foller S; Oppel-Heuchel H; Grimm MO
Urologe A; 2018 Nov; 57(11):1316-1325. PubMed ID: 30334063
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
[TBL] [Abstract][Full Text] [Related]
5. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of Renal Cell Carcinoma].
Poprach A; Lakomý R; Büchler T
Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
[TBL] [Abstract][Full Text] [Related]
7. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
Oppel-Heuchel H; Grimm MO
Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
[TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression: an indicator for cure in combined immunotherapy?
Zhao L; Yang Y; Li W; Li T; Han L; Lin H; Gao Q
Immunotherapy; 2019 Sep; 11(13):1087-1093. PubMed ID: 31361166
[TBL] [Abstract][Full Text] [Related]
9. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
Bedke J; Stühler V; Todenhöfer T; Stenzl A
Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
11. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
12. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Vano YA; Simonaggio A; Thibault C; Oudard S
Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
[TBL] [Abstract][Full Text] [Related]
14. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
[TBL] [Abstract][Full Text] [Related]
15. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier A; Baldini C; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2018 Sep; 101():160-164. PubMed ID: 30071444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
